Federal Register / Vol. 62, No. 23 / Tuesday, February 4, 1997 / Notices 5241

Room 9C10, Bethesda, MD 20892, (301) 496–

9223.

Purpose/Agenda: To review and evaluate 1

SBIR Phase I Topic 027 Contract Proposal.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program No. 93.853, Clinical Research

Related to Neurological Disorders; No.

93.854, Biological Basis Research in the

Neurosciences).

Dated: January 29, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97–2730 Filed 2–3–97; 8:45 am]

BILLING CODE 4140–01–M

Division of Research Grants; Notice of

Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Division

of Research Grants Special Emphasis

Panel (SEP) meetings:

Purpose/Agenda: To review individual

grant applications.

Name of SEP: Clinical Sciences.

Date: February 20, 1997.

Time: 11:00 a.m.

Place: Holiday Inn, Chevy Chase, MD.

Contact Person: Dr. Jerrold Fried, Scientific

Review Administrator, 6701 Rockledge Drive,

Room 4126, Bethesda, Maryland 20892, (301)

435–1777.

Name of SEP: Biological and Physiological

Sciences.

Date: March 6 1997.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 6168,

Telephone Conference.

Contact Person: Dr. Syed Amir, Scientific

Review Administrator, 6701 Rockledge Drive,

Room 6168, Bethesda, Maryland 20892, (301)

435–1043.

Name of SEP: Clinical Sciences.

Date: March 18, 1997.

Time: 12:00 p.m.

Place: NIH, Rockledge 2, Room 4126,

Telephone Conference.

Contact Person: Dr. Jerrold Fried, Scientific

Review Administrator, 6701 Rockledge Drive,

Room 4126, Bethesda, Maryland 20892, (301)

435–1777.

The meetings will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Nos. 93.306, 93.333, 93.337, 93.393–

93.396, 93.837–93.844, 93.846–93.878,

93.892, 93.893, National Institutes of Health,

HHS)

Dated: January 29, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97–2729 Filed 2–3–97; 8:45 am]

BILLING CODE 4140–01–M

Substance Abuse and Mental Health

Services Administration

Current List of Laboratories Which

Meet Minimum Standards To Engage in

Urine Drug Testing for Federal

Agencies, and Laboratories That Have

Withdrawn From the Program

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS

(Formerly: National Institute on Drug

Abuse, ADAMHA, HHS).

ACTION: Notice.

SUMMARY: The Department of Health and

Human Services notifies Federal

agencies of the laboratories currently

certified to meet standards of Subpart C

of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59

FR 29916, 29925). A similar notice

listing all currently certified laboratories

will be published during the first week

of each month, and updated to include

laboratories which subsequently apply

for and complete the certification

process. If any listed laboratory’s

certification is totally suspended or

revoked, the laboratory will be omitted

from updated lists until such time as it

is restored to full certification under the

Guidelines.

If any laboratory has withdrawn from

the National Laboratory Certification

Program during the past month, it will

be identified as such at the end of the

current list of certified laboratories, and

will be omitted from the monthly listing

thereafter.

FOR FURTHER INFORMATION CONTACT: Mrs.

Giselle Hersh, Division of Workplace

Programs, Room 13A–54, 5600 Fishers

Lane, Rockville, Maryland 20857; Tel.:

(301) 443–6014.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal

Workplace Drug Testing were developed

in accordance with Executive Order

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines,

‘‘Certification of Laboratories Engaged

in Urine Drug Testing for Federal

Agencies,’’ sets strict standards which

laboratories must meet in order to

conduct urine drug testing for Federal

agencies. To become certified an

applicant laboratory must undergo three

rounds of performance testing plus an

on-site inspection. To maintain that

certification a laboratory must

participate in a quarterly performance

testing program plus periodic, on-site

inspections.

Laboratories which claim to be in the

applicant stage of certification are not to

be considered as meeting the minimum

requirements expressed in the HHS

Guidelines. A laboratory must have its

letter of certification from SAMHSA,

HHS (formerly: HHS/NIDA) which

attests that it has met minimum

standards.

In accordance with Subpart C of the

Guidelines, the following laboratories

meet the minimum standards set forth

in the Guidelines:

Aegis Analytical Laboratories, Inc., 624

Grassmere Park Rd., Suite 21,

Nashville, TN 37211, 615–331–5300

Alabama Reference Laboratories, Inc.,

543 South Hull St., Montgomery, AL

36103, 800–541–4931 / 334–263–5745

American Medical Laboratories, Inc.,

14225 Newbrook Dr., Chantilly, VA

22021, 703–802–6900

Associated Pathologists Laboratories,

Inc., 4230 South Burnham Ave., Suite

250, Las Vegas, NV 89119–5412, 702–

733–7866 / 800–433–2750

Associated Regional and University

Pathologists, Inc. (ARUP), 500 Chipeta

Way, Salt Lake City, UT 84108, 801–

583–2787 / 800–242–2787

Baptist Medical Center—Toxicology

Laboratory 9601 I–630, Exit 7, Little

Rock, AR 72205–7299, 501–227–2783,

(formerly: Forensic Toxicology

Laboratory Baptist Medical Center)

Bayshore Clinical Laboratory 4555 W.

Schroeder Dr., Brown Deer, WI 53223,

414–355–4444 / 800–877–7016

Cedars Medical Center, Department of

Pathology 1400 Northwest 12th Ave.,

Miami, FL 33136, 305–325–5784

Centinela Hospital Airport Toxicology

Laboratory 9601 S. Sepulveda Blvd.,

Los Angeles, CA 90045, 310–215–

6020

Clinical Reference Lab, 8433 Quivira

Rd., Lenexa, KS 66215–2802, 800–

445–6917

CompuChem Laboratories, Inc., 1904

Alexander Drive, Research Triangle

Park, NC 27709, 919–549–8263/800–

833–3984, (Formerly: CompuChem

Laboratories, Inc., A Subsidiary of

Roche Biomedical Laboratory, Roche

CompuChem Laboratories, Inc., A

Member of the Roche Group)

Cox Health Systems, Department of

Toxicology, 1423 North Jefferson

Ave., Springfield, MO 65802, 800–